Skip to main navigation
Supernus Pharmaceuticals

Header Links

  • Return to Supernus.com

Investor Relations

  • Overview
  • News & Events
    Press Releases Events & Presentations
  • Governance
    Corporate Governance Management Board of Directors Committee Composition Contact the Board
  • Financials & Filings
    Financials & Filings SEC Filings Annuals & Proxies Quarterly Results
  • Stock
    Stock Information Historic Stock Lookup Investment Calculator Ownership Profile
  • Contact Us

Investor Relations

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Governance
    • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials & Filings
    • Financials & Filings
    • SEC Filings
    • Annuals & Proxies
    • Quarterly Results
  • Stock
    • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Ownership Profile
  • Contact Us

    Breadcrumb

  1. Investor Relations
  2. Press Releases

Press Releases

Date Title  
June 2, 2022
Supernus to Participate in the Jefferies Healthcare Conference
PDF Version
May 9, 2022
Supernus Announces First Quarter 2022 Financial Results
PDF Version
May 2, 2022
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
PDF Version
April 29, 2022
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
PDF Version
April 13, 2022
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
PDF Version
April 4, 2022
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
PDF Version
March 17, 2022
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
PDF Version
March 2, 2022
Supernus to Participate in Annual Cowen Health Care Conference
PDF Version
February 28, 2022
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
PDF Version
February 22, 2022
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 11

Shareholder Tools


Email Alerts


RSS Feeds


Search

Back to Top
Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
Rockville, MD 20850
(301) 838-2500
info@supernus.com

Back to Top

© 2022 Supernus Pharmaceuticals

Post Footer Links

  • Sitemap
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • State Policy
  • Social Media Community Guidelines